UK government has backed five new centres for AI in health, which will be focusing on areas that includes pathology, radiology and imaging. Centres will be based in Leeds, Oxford, Coventry, Glasgow and London. Utilising £50m in funding, the new centres will bring together doctors, businesses and academics to collaborate on the development of products
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, with the aim to run clinical trials of Adaptimmune’s potential immunotherapy as a treatment for one of the rarest soft tissue cancers in the world.
Novo Nordisk has confirmed that they are investing around 750 million kroner (roughly equivalent to $130 million) on new diabetes laboratories at the R&D campus in Måløv, Denmark. Construction of the new laboratories has already started and the new facility, to be named the Diabetes Research House, will open in early 2016. The Diabetes Research
Governments in Europe must to do a lot more to ensure R&D innovation in the biotechnology industry is converted into new companies, new products and extra jobs, according to a new report released earlier today. The report, titled “What Europe has to offer biotechnology companies: unravelling the tax, financial and regulatory framework”, was launched by
The UK’s SkyePharma has succeeded in salvaging some jobs which were threatened by cost-cutting at their Research and Development facility in Muttenz, Switzerland. The jobs were saved as a result of consolidating their relationship with Aenova, the German group whose French subsidiary leased SkyePharma’s manufacturing department at Saint Quentin-Fallavier, Lyon in August 2011.
Earlier today Roche announced the opening of their new R&D office in Basel, Switzerland. The building, which represents an investment of CHF 250 million, will be used to study and develop pharmaceutical formulations for new active ingredients, as well as produce supplies for global clinical trials. Headquartered in Basel, Roche is a leader in research-focused
A new study has found that leading research-based pharmaceutical firms have seen the average quantity of compounds in their late-stage development pipelines drop by 22% this year, while R&D costs have increased by over 25%. According to the 2011 yearly review of pharmaceutical R&D value, Measuring the Return from Innovation, by Deloitte and Thomson Reuters,